Story
Nanexa Shares Double on $1.3 Billion Drug Delivery Deal with Novo Nordisk
Summary
Swedish drug-delivery firm Nanexa saw its stock surge after announcing a global licensing agreement with Novo Nordisk potentially worth $1.3 billion. The collaboration will use Nanexa's PharmaShell technology to develop long-acting treatments for obesity and diabetes.
Shares of Swedish drug-delivery company Nanexa surged more than 110% after it announced a global licensing and collaboration agreement with Novo Nordisk. The deal, focused on developing long-acting treatments for obesity and diabetes, could be worth up to €1.165 billion ($1.3 billion).
Agreement Details
Under the terms announced after U.S. market hours on Thursday, Novo Nordisk gains an exclusive worldwide license to Nanexa’s PharmaShell platform for use in up to five development programs. These programs will target obesity, type 2 diabetes, and other cardiometabolic conditions.
The financial structure of the deal includes:
- Total potential payments of up to €1.165 billion.
- €615 million in upfront payments and payments tied to development and regulatory milestones.
- The remainder is linked to achieving specific sales milestones.
- Nanexa is also eligible for low-single-digit royalties on global net sales of any commercialized products.
Novo Nordisk will be responsible for the global development and commercialization of any therapies that result from the partnership, according to the announcement.
AdStrategic Rationale and Technology
The collaboration aims to leverage Nanexa’s proprietary PharmaShell technology to create long-acting injectable drug formulations. The goal is to extend dosing intervals to a monthly or even quarterly basis, a significant potential improvement over the weekly injections common for current treatments in the rapidly growing obesity and diabetes markets.
PharmaShell is a drug delivery platform based on atomic layer deposition (ALD). This technology applies an ultra-thin, inorganic coating to individual drug particles, enabling a controlled and sustained release of the active pharmaceutical ingredient once administered. Nanexa stated the partnership brings together its platform with Novo Nordisk's expertise in metabolic disease treatments.
Market Reaction
Following the news, shares of Nanexa jumped 114% in early Friday trading, according to Investing.com. The significant stock price movement reflects investor optimism about the validation of Nanexa's technology and the substantial financial potential of the collaboration with a global pharmaceutical leader.
Read next
More on Stocks
EssilorLuxottica Valuation Contracts Sharply Amid Profitability Concerns
Shares of EssilorLuxottica have fallen over 46% year-to-date, creating a more attractive valuation for the eyewear giant. However, investors are weighing this against clear signs of margin pressure and declining net income, raising questions about the stock's near-term prospects.
Akamai Stock Soars on $11.6 Billion AI Cloud Deal with Anthropic
Akamai Technologies announced a seven-year, $11.6 billion cloud services contract with AI firm Anthropic, sending its shares soaring on the prospect of long-term revenue growth and a major win in the competitive AI infrastructure market.
Banca Ifis Stock Plummets 12% After Bank of Italy Finds Control Deficiencies
Shares in the Italian lender fell sharply after a central bank inspection revealed critical issues in governance and risk management, prompting a review for potential additional capital requirements.
Tandem Group Shares Surge on Return to Profitability, Revenue Growth
Shares of the AIM-listed sports and leisure products company jumped nearly 8% after it reported a 6.7% rise in first-half revenue and a swing to profit from a loss in the prior year.